These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19451340)

  • 21. [Long-term virus suppression. Expanding therapy options with protease inhibitor].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():68-9. PubMed ID: 16385882
    [No Abstract]   [Full Text] [Related]  

  • 22. Heart attack warning issued.
    AIDS Patient Care STDS; 2010 Jan; 24(1):65-6. PubMed ID: 20169638
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA notifications. FDA approves new formulation of Lexiva.
    AIDS Alert; 2007 Aug; 22(8):90-1. PubMed ID: 17768778
    [No Abstract]   [Full Text] [Related]  

  • 24. Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
    DeJesus E; Piliero PJ; Summers K; Wire MB; Stein DS; Masterman A; Lou Y; Min SS; Shelton MJ
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3157-9. PubMed ID: 16940117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amprenavir: a new HIV protease inhibitor.
    Med Lett Drugs Ther; 1999 Jul; 41(1057):64-6. PubMed ID: 10436772
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
    Guaraldi G; Cocchi S; Codeluppi M; Di Benedetto F; Bonora S; Motta A; Luzi K; Pecorari M; Gennari W; Masetti M; Gerunda GE; Esposito R
    Transplant Proc; 2006 May; 38(4):1138-40. PubMed ID: 16757288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amprenavir made available through early access program.
    AIDS Patient Care STDS; 1998 Dec; 12(12):939-40. PubMed ID: 11362067
    [No Abstract]   [Full Text] [Related]  

  • 28. Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline.
    Corbett AH; Kashuba AD
    Curr Opin Investig Drugs; 2002 Mar; 3(3):384-90. PubMed ID: 12054084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raltegravir can be used safely in HIV-1-infected patients treated with warfarin.
    Honda H; Gatanaga H; Aoki T; Watanabe K; Yazaki H; Tanuma J; Tsukada K; Honda M; Teruya K; Kikuchi Y; Oka S
    Int J STD AIDS; 2012 Dec; 23(12):903-4. PubMed ID: 23258834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency.
    Torres HA; Barnett BJ; Arduino RC
    Clin Infect Dis; 2007 Mar; 44(6):887-8. PubMed ID: 17304468
    [No Abstract]   [Full Text] [Related]  

  • 31. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.
    Pea F; Tavio M; Pavan F; Londero A; Bresadola V; Adani GL; Furlanut M; Viale P
    Antivir Ther; 2008; 13(5):739-42. PubMed ID: 18771060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NEAT trial releases results.
    AIDS Patient Care STDS; 2002 Dec; 16(12):617. PubMed ID: 12881881
    [No Abstract]   [Full Text] [Related]  

  • 33. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 34. From amprenavir to GW433908.
    Gatell JM
    J HIV Ther; 2001 Nov; 6(4):95-9. PubMed ID: 11740410
    [No Abstract]   [Full Text] [Related]  

  • 35. Fosamprenavir: advancing HIV protease inhibitor treatment options.
    Becker S; Thornton L
    Expert Opin Pharmacother; 2004 Sep; 5(9):1995-2005. PubMed ID: 15330736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA notifications. Fosamprenavir label is updated.
    AIDS Alert; 2008 Feb; 23(2):21-2. PubMed ID: 18578033
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA approves Lexiva.
    IAPAC Mon; 2003 Nov; 9(11):280. PubMed ID: 14989187
    [No Abstract]   [Full Text] [Related]  

  • 38. [Two year use of Telzir: what are the perspectives?].
    Med Mal Infect; 2007 Mar; 37(3):181-6. PubMed ID: 17552082
    [No Abstract]   [Full Text] [Related]  

  • 39. Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.
    Schürmann D; Elston R; Xu F; Kleinkauf N; Wünsche T; Suttorp N
    AIDS; 2006 Jan; 20(1):138-40. PubMed ID: 16327339
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevention of stroke in patients with atrial fibrillation.
    Med Lett Drugs Ther; 2009 Jun; 51(1313):41. PubMed ID: 19478692
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.